Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

Non‐small cell lung cancer (NSCLC) affects 10–50% of patients with epidermal growth factor receptor (EGFR) mutations. Osimertinib is a third‐generation EGFR tyrosine kinase inhibitor (TKI) that radically changes the outcome of patients with tumors bearing EGFR sensitizing or EGFR T790M resistance mu...

Full description

Bibliographic Details

Published in:	FEBS Open Bio
Main Authors:	David Barthélémy, Arnaud Vigneron, Xavier Rousset, Jérome Guitton, Emmanuel Grolleau, Margaux Raffin, Julie Balandier, Gaëlle Lescuyer, Mathilde Bardou, Florence Geiguer, Sébastien Couraud, Claire Bardel, Jean Viallet, Nazim Benzerdjeb, Léa Payen
Format:	Article
Language:	English
Published:	Wiley 2025-05-01
Subjects:	chicken chorioallantoic membrane epidermal growth factor receptor non‐small cell lung cancer transcriptomics analysis
Online Access:	https://doi.org/10.1002/2211-5463.13970